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Section I: Why evaluate?
The primary role ofthe clinical chemist is to ensure the provision
of diagnostic laboratory services that provide optimal patient
care and are as excellent as available technology and local
economic factors will allow. However, an acceptable service is
provided only if high standards of analytical performance are
achieved and maintained. To monitor analytical performance,
most laboratories use comprehensive internal and external
quality control and assurance programmes. It should be re-
alized, however, that the strategy of these schemes is to compare
present performance with previous performance and not to
provide data on whether the method itself is capable of fulfilling
the analytical and clinical performance standards required.
Thus, before a method is brought into routine service in any
laboratory, even the smallest, it is necessary to objectively assess
the method itself, not only in terms of its analytical character-
istics and ability to fulfill clinical needs, but also its impact on the
laboratory, staff and budget. To obtain the data that allow a
method to be so fully defined means that a proper and full
evaluation must be carried out. It is preferable to do such an
evaluation before a method (whether an instrument or reagent
kit set) is purchased, but methods that are already purchased,
even if in use for some time, should also be subjected to the same
close scrutiny ofevaluation. Once the evaluation has been made,
the method is fully characterized. The data generated can then
be retained in the laboratory; only then can quality control and
assurance programmes be instituted and used to ensure that the
well-defined and acceptable analytical performance of the
method is being maintained.
The total evaluation process should be a logical progression
through the steps of pre-purchase or pre-service assessment,
familiarization, evaluation and objective assessment of
acceptability. None of these steps should be omitted before a
candidate method is brought into routine service.
Many evaluation protocols have been published in the
literature of clinical chemistry. Most of these are well thought-
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out and carefully written. They tend, however, to be written for
the expert and are consequently somewhat theoretical. A brief.
working guide for the clinical chemistry ’layman’ has until now
been lacking. This publication provides such a practical guide--
a route-map for the driverwho has either never been on this road
before or is not very familiar with the terrain.
The ’Evaluation Kit’ is simple to use. Section II contains
the terms and phrases used in evaluation theory and practice;
this may be omitted by those familiar with field. Sections III to
IX provide the detailed route-map, starting with the itinerary,
and then progressing in a logical manner through the stages of
the evaluation process.
This material is based on practical experience, on theory, on
previously published work and on current national and inter-
national recommendations. Major sources of information are
acknowledged in the Bibliography (Section X).
Section II: Terminology
Many of the definitions of the terms and phrases used in clinical
chemistry are yet to be agreed upon universally. In this
publication, the definitions promulgated by the International
Federation of Clinical Chemistry are generally used.
Aliquot:
Analyte:
Analytical ranTe:
Assigned value:
Bias:
Batch:
A measured portion ofa whole having the
same composition,
The component to be measured.
The range of concentration (or other
quantity) in the specimen over which the
method is applicable without
modification.
Value assigned either arbitrarily or from
preliminary evidence.
The same as inaccuracy.
The same as run.Calibration: The procedure of relating a reading to the
quantity required to be measured.
Carry-over: The influence of a sample on a following
one.
Comparative method: A method to which the test method is
Consensus value:
Control material:
Definitive method:
Detection limit:
Error:
External quality
assurance:
Imprecision:
Inaccuracy:
Interference:
Matrix:
Primary standard:
Reading:
Reagent kit set:
Recovery:
Reference method:
Reference interval:
Replicate:
Result:
compared. The characteristics of such a
method should be known.
Value derived from a set of results.
Material. used for quality control
purposes.
A method which after exhaustive investig-
ation has been shown to have no known
source of inaccuracy or ambiguity.
The smallest single result which, with a
stated probability, can be distinguished
from a true blank.
Difference between an estimate ofa quan-
tity and its true value.
Procedure of utilizing, for quality control
purposes, the results of several labora-
tories which analyse the same specimens.
Standard deviation or coefficient of vari-
ation of the results in a set of replicate
experiments.
Numerical difference between the mean of
a set of replicate measurements and the
true value.
The effect ofa component, which does not
by itself produce a reading, on the ac-
curacy of measurement of another
component.
The nature of the sample itself.
A primary standard solution is used as a
calibration standard in which the con-
centration is determined solely by dis-
solving a weighed amount of a substance,
ofknown chemical composition and suffi-
cient purity (a primary standard
material), in an appropriate solvent and
making to a stated volume or weight.
The value indicated on the scale of an
instrument or analytical device.
Two or more different clinical or general
laboratory materials (excluding recon-
stituting materials), with or without other
components, packaged together, and de-
signed for the performance ofa procedure
for which directions are supplied with the
package.
The ability of an analytical method to
estimate pure analyte added to the
sample.
A method which after exhaustive investig-
ation has been shown to have negligible
inaccuracy in comparison to its
imprecision.
A range of values with which an observed
value is compared for interpretative
purposes.
Analysis of the same sample a number of
times.
Final value obtained for a measured
quantity after performing a measuring
procedure, including all sub-procedures
and laboratory evaluations.
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Run:
Sample:
Specificity:
Specimen:
Standard:
A set of consecutive assays performed
without interruption. The results are usu-
ally calculated from the set of calibration
standard reading.
The appropriately representative part ofa
specimen which is used in the analysis.
The ability of a method to determine
solely the component(s) it purports to
measure.
The material available for analysis.
Material or solution with which the
sample is compared in order to determine
the concentration (or other quantity).
Stated value: A value stated without official
certification.
True value: The correct concentration (or other
quantity).
The following statistical terms are used in the ’Evaluation Kit’:
Coefficient of
variation C V):
Correlation co-
efficient (r):
F-test:
Intercept:
Linear regression
analysis:
Mean:
Outliers:
Slope:
Standard deviation:
t-Test:
Relative standard deviation, the standard
deviation expressed as a fraction of the
mean.
A statistic which estimates the degree of
association between two variables.
A statistical test in which the differences
between two variances (squares of stan-
dard deviations) is tested for significance.
The test investigates the hypothesis that
there is no difference between the two
variances.
The place at which a line on a graphical
plot intersects an axis.
A technique for estimation ofthe best linear
relationship between two variables.
The arithmetic average of a set of data.
Values which do not agree with the
majority of values.
The angle ofa line on a graph expressed as
a ratio of y-units to x-units.
A statistic which describes the dispersion
of a set of values about the mean.
A statistical test used to assess the
difference between means.
Section III: The evaluation itinerary
There are six stages in any evaluation:
(1) Pre-evaluation assessment.
(2) Familiarization.
(3) Evaluation.
(4) Specific studies.
(5) Assessment of performance.
(6) Introduction to routine service.
The rationale of each of these necessary stages is briefly
outlined in the following.
(1) Pre-evaluation assessment
The objective evaluation that must be performed on an instru-
ment or reagent kit set before it is purchased and introduced
into routine laboratory service uses both materials and time.
Thus, it is generally not sensible or cost-effective to fully assess
all the available commercial options (candidate methods) in the
laboratory. It is therefore necessary to make a pre-selection of
preferably not more than three options, these being the candi-
dates that appear to be the most serious contenders for the final
choice. Such a pre-selection is often based on no more than a
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superficial impression ofpotential suitability that may have been
gained from commercial advertising, published evaluations or
the previous experience ofcolleagues. The pre-selection problem
may be simplified if there are few commercially available
candidates.
The one, two or three likely candidates are first subjected to a
pre-evaluation assessment, the object of which is to determine
whether the candidate is likely to:
(a) Perform all or part of the clinical task required.
(b) Harmonize with the current laboratory organization
and philosophy.
(c) Be economic.
(d) Not become quickly out-dated.
Completion of the pre-evaluation assessment should allow
an objective selection of a single candidate that fulfills sufficient
criteria to warrant laboratory evaluation.
(2) Familiarization
When a candidate becomes the test method (that is, it has arrived
at the laboratory either as a firm purchase or on loan for
evaluation) it should, if possible, be located and used at the site
selected for its planned routine use. The use of a separate
evaluation area and specialist staffmay not reveal problems that
could arise when the test method is introduced into the routine
laboratory.
Once installed, the test method must undergo a familiariz-
ation period, during which time the instrument or reagent kit set
is generally examined and used according to the manufacturer’s
instructions. Prior to commencing the familiarization period,
steps must be taken to ensure that the staff who are to perform
the evaluation are well-trained and competent, and that all basic
laboratory equipment, such as pipettes, balances and
waterbaths, which are ancillary requirements for the technique,
are satisfactory. During the familiarization period, a general
impression of the following points should be gained:
Is the test method:
(a) Doing more or less what was expected?
(b) More difficult to operate than expected?
(c) Showing no major problems with siting, services, or
safety?
(d) Acceptable to staff2.
(e) Acceptable to the manufacturer’s representatives, if the
method has been provided for trial?
At the conclusion of the familiarization period, decisions are
made as to whether the test method is likely to fulfill the needs of
the laboratory and whether a formal evaluation should be
initiated.
before a decision on acceptance can be taken and subsequent
introduction to service initiated.
If the test method has been in general routine use for some
time, it is likely that one or more independent and full
evaluations will have been published; these are usually readily
obtainable. The steps and criteria used in the evaluation should
be checked against those recommended in one or more authora-
tive references (see Bibliography in Section X). If the evaluation
report appears to be satisfactory, it is necessary only to ensure
that the test method will perform in a similar or satisfactory way
in the laboratory. In this case a modified or short evaluation
provides adequate information for an informed decision to be
made as to suitability.
(4) Specific studies
Evaluation protocols are designed to elicit (from any analytical
system) the basic data that allow the general performance
characteristics of that method to be defined. However, any
evaluation protocol is unavoidably general in its approach and
therefore specific studies that explore the unique properties ofthe
method under consideration may have to be designed and
executed in the laboratory. Relevant protocols are often avail-
able in the literature.
Disappointing or poor evaluation results should not lead to
an automatic rejection of the test method. Instead, specific
studies should be carried out in an attempt to identify whether
one or more components of the test method, or associated in-
house equipment, are making a significant contribution to the
unacceptable performance.
Specific studies are also intended to reveal any factors that, in
the future, may compromise the performance of the method
during the evaluation. The performance characteristics them-
selves may also be improved by use ofknowledge gained in these
special studies. Since the range ofmethods in current use is wide,
it will be possible for this publication to provide only an
indication of the areas in which specific studies would be of
major benefit.
(5) Assessment of performance
Having produced a large quantity of objective information
during a short or full evaluation, it is then necessary to decide
whether the data indicate that the test method can undertake the
alloted task(s) in the routine service laboratory. This is the
crucial decision that may lead to a successful installation or an
expensive failure. Objective criteria must be strictly applied at
this stage.
After short or full evaluation, a final decision can be taken on
the ’where, how and when’ of the role of the test method in the
routine service of the laboratory.
(3) Evaluation
A newly launched instrument or reagent kit set may be accom-
panied by an instruction manual that includes briefand selected
details of the performance obtained by the manufacturer. Such
data have been generally obtained under ideal conditions, either
in the research and development laboratories of the manu-
facturer or at one or two selected external centres. The
performance details quoted are only a guide and do not
guarantee similar results in the working laboratory.
If an independent evaluation of the test method using
accepted criteria is unavailable as a paper in a reputablejournal
then a .full evaluation must be carried out by the laboratory
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(6) Introduction to routine service
The ease with which the new method is slotted into the routine
work of the laboratory depends both on its complexity and on
whether it was evaluated at its future work-site by the routine
staff or elsewhere by staff that specialize in evaluation. This last
stage of bringing a new method on-line is concerned with such
points as:
(a) Are all staffwho are liable to use the method adequately
trained?
(b) Are trouble-shooting and maintenance schedules
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(c) Are adequate reagents and spares available?
(d) Are adequate quality control data and internal quality
control and external quality assurance programmes
available?
(e) Are laboratory users aware of any consequent change in
specimen requirements or reference intervals?
(f) Have specific studies, or action required, been taken to
ensure that the evaluation performance characteristics
will prevail for all specimens and conditions that may be
encountered by the new method in the future?
(9) Is the manufacturer, or his agent, satisfied with the
performance of the instrument or method?
Commercial choices available
for new method
Pre-evaluation
assessment
Newly purchased 1 method
Familiarization
Short evaluation New method
Well-established method
Specific studies
Assessment of performance
Introduction to service
Full evaluation
Figure 1. The evaluation itinerary.
Section IV: Pre-evaluation assessment
Aims
(1) To define the function, performance characteristics and
other factors that are ideally required by the laboratory
for its new method.
(2) To identify the candidate method that is most likely to
fulfill the total specification.
The assessment of the candidates should be made using the
detailed check-list in figure 2.
Notes on the check-list (figure 2)
(1) Candidates
Ideally no more than three candidate instruments or reagent kit
sets should be considered. The primary selection is often made
on impressions gained from commercial advertising or exhi-
bitions, or on performance reports from colleagues, or the
literature. Record brief identifying details of the candidates that
have been selected.
(2) Analytical features
(a) Analytes: list the analyte estimations required by the
laboratory and those that are offered by each candidate.
(b) Analytical flexibility: only performs full range of analytes
offered=FULL;
performs full analyte range, but suppresses unwanted
test results- SEMI;
performs only tests selected from analytes offered
=SELECT.
Record combination of tests required and that
offered by each candidate.
(c) Patient type.
Record: adult, child, infant, neonate.
(d) Sample type.
Record: blood, plasma, serum, urine, CSF, synovial,
pleural, other.
(e) Sample volume:
Record: sample volume(s) required and used.
(3) Service needs
(a) Routine/emergency.
Record whether analyses are required and can be
performed either in routine (R), emergency (E), or both
situations (R+ E).
(b) Immediate emergency mode.
Record ability during a routine run to analyse an
emergency specimen as the next specimen without
compromising the routine run or specimen identi-
fication.
(4) Analytical performance
(a) Published evaluation.
Record whether partial or full evaluation(s) are
available, and references.
(b) Year candidate method introduced.
Record year when instrument or reagent kit set first
became commercially available.
(c) Standards or mode of calibration.
Record whether standards, primary or secondary, or
calibration factors are used.
(d) Assignment of standard value.
Record mode that has been used to assign value to
standard. For example, the standards provided with
radioimmunoassay kits for peptides and proteins are
generally calibrated against various international
preparations or primary standards (World Health
Organization, Medical Research Council, etc.).
(e) Reference intervals.
Record current reference intervals used by labora-
tory and those quoted by manufacturer.
(f) Throughput time.
sample (ready): the time required to produce a
single patient result when the method is already prepared
for immediate operation (include standards and appro-
priate quality control).
Instruments: warmed up and calibrated.
Reagent kit sets: reagents already prepared.
sample (cold): the time required to provide a patient
result when the method is in an unprepared state.
Rate: the number of samples (test, standard or
quality control) that can be processed in a selected time
period, for example instruments: x samples/hour if the
rate of analysis can be maintained each hour; reagent kit
sets: x samples/two days may be typical of a lengthy
radio-immunoassay method.
(9) Between-day imprecision (SD or CV).
Sales literature normally provides some basic per-
formance data, usually both between-day and within-
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Figure 2. Pre-evaluation assessment.
(1) Model/name
Manufacturer
Sample available for evaluation
Laboratory space required
(2) Analytical features
(a) Analytes
(b) Analyte flexibility
(c) Patient type
(d) Sample type
(e) Sample volume
Fixed
Various
Variable range
(f) Maximum batch size per run
(g) Units of test results
Comments:
(3) Service needs
(a) Routine, emergency
(b) Immediate emergency mode
Comments:
(4) Analytical performance
(a) Published evaluation
References
(b) Year candidate method introduced
(c) Standards or calibrators supplied
(d) Assignation of standard value
(e) Manufacturer’s suggested
reference interval
(f) Throughput time for:
sample (ready)
sample (cold)
rate (routine)
(g) Between-day imprecision
(CV) Low
Med.
High
(a) Manufacturer’s data
(b) Published evaluation
Comments:
(5) Stafffactors
(a) Operator skill (routine/out-of-hours)
(b) Additional staff
(c) Training of present staff
(d) Safety hazards
Comments:
Laboratory
requirement
#l/ml
#l/ml
#l/ml
R, E, R+E
#l/ml
#l/ml
#l/ml
R, E, R+E
N Y
Present interval:
Present method:
N
N
a b
Y N
Y N
Y N
Candidates
#l/ml
#l/ml
#l/ml
R, E, R+E
N Y
N Y
a b
Y N
Y N
Y N
#l/ml
#l/ml
#l/ml
R, E, R+E
N Y
N Y
a b
Y N
Y N
Y N
continued
run imprecision for analyses of quality control materials.
These values should be recorded and compared with the
published data, if available. Care should be taken in
noting whether the data were derived from a meaningful
number of experimental measurements at relevant levels
of analyte in an appropriate matrix.
(5) Stafffactors
(a) Operator skill required.
Record whether satisfactory operation is possible by:
untrained new staff, experienced technician, graduate,
other (both for routine and out-of-hours services).
(b) Additional staff needed.
Record whether additional staff will be required.
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(c) Training of present staff.
Record whether training of staff will require sig-
nificant time.
(d) Safety hazards.
Record potential hazards, for example radioisotopes,
corrosive chemicals, potential carcinogens.
(6) Laboratory supplies
Record:
(a) Whether the laboratory requires reagents to be
supplied ready-made and whether the manufacturer is
able to supply these. Record alternative suppliers and
note their previous record of reliability.Figure 2.
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Pre-evaluation assessment (continued).
(6) Laboratory supplies
(a) Reagents supplied
(b) Reagent formulae provided
(c) Disposable items required
(i)
(ii)
(iii)
(iv)
(d) Additional equipment required
(i) Available and compatible
(e) Additional equipment requiring purchase
Nature and approximate cost
(f) Built-in fault diagnosis
(9) Capable of in-house routine maintenance
(h) Local manufacturer-trained engineer/agent
(i) Spares always stocked by local agent
Comments:
(7) Services
(a) Overall dimensions
(b) Structural changes to laboratory
(c) Adequate facilities already available for:
Electricity
Water
Drainage
Ventilation
Solvent disposal
Radiation disposal
Comments:
(8) Economics
(a) Capital cost
(b) Working life of method
(c) Cost per sample
Cost per run (reagents and disposables only)
(d) Annual cost of routine maintenance spare parts
(e) Cost of annual maintenance contract
Comments:
(9) Decision
Number of features compatible with
laboratory requirement
(1 O) Order of preference
Comments:
Laboratory
requirement
Y N
Y N
Y N
Y N
Y N
Budget:
Present method:
Candidates
Y N
Y N
Y N
Y N
N
N
N
N
N
N
N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
Y N
continued
(b) User preference to produce reagents if the formulae are
provided.
(c) Disposable items such as pipette tips, tubes or vials that
have to be supplied by the user.
(d) Equipment to be provided by the laboratory, for
example dispensers, centrifuge, water-bath, spectro-
photometer (note wavelength requirement).
(e-f) Other materials, spares and ma.intenance and service
expertise supplied, or potentially supplied, by the
manufacturer and/or required by the laboratory are
recorded in the appropriate sections of the check-list.
(7) Services
The work space, laboratory structural changes and services
required are recorded in the appropriate sections of the check-
list.
(8) Economics
The capital cost, period of amortization and likely running costs
are recorded appropriately.
(9) Decision
A pre-evaluation assessment cannot provide a decision from a
simple generation and inspection of the final score reached by
each candidate. It does, however, allow a rapid identification
and collation of the method features that are important and
desirable to the laboratory and also identifies how far each
candidate satisfies or falls short ofthe ideal. After this assessment
has been performed, it should be possible to rank the candidates
in order of preference and make a decision on whether the first
choice is sufficiently suitable to warrant an example being
obtained and evaluated in the laboratory (the test method).
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Section V: Familiarization
The aim of the familiarization period is to ensure, as far as
possible, that the test method selected from the candidates will
be evaluated under conditions that:
(1) Do not compromise the potential of the method.
(2) Represent the ideal laboratory conditions that would
prevail for routine use.
After installation of the test method in the laboratory and
checking the performance of all ancillary equipment required,
the staff performing the initial study should accustom them-
selves to the preparation of reagents, samples and the basic
operations ofthe system. When confident, the operator(s) should
analyse a small number of samples, preferably using quality
control and patient samples with known values. During the
period, the familiarization check-list (figure 3) is completed.
The check-list is mainly self-explanatory: the following brief
notes are provided to assist the evaluators:
(1) If the test method is first set up and run in a special
section for evaluation, particularly if staffed by indiv-
iduals who will not be the routine users, then the
evaluators should attempt to delineate potential pro-
blems that may arise when the test method is transferred
to the routine location, for example space requirements,
service facilities, staff skills and special techniques.
(5) If the components provided by the manufacturer (for
example tubes) are not compatible with existing equip-
ment (for example gamma counter), or are less than
satisfactory (for example having to use a 200/A and a
100 #1 pipette to dispense 300 #1), steps to rectify the
deficiency should be taken before proceeding to an
evaluation.
Section VI: Evaluation protocol
(1) Inaccuracy and within-run imprecision
Inaccuracy and within-run imprecision can be assessed by
various experimental approaches. The experimental scheme
detailed here is particularly useful when only briefassessments of
inaccuracy and imprecision are required; in addition, the results
also provide information on linearity andmay indicate pote0tial
interferences. The following experimental procedure should be
carried out to provide a short evaluation.
Procedure
Analyse a number of samples obtained from specimens from
patients (at least 40 and preferably 100) in duplicate by the test
method. The sample duplicates should be within the same
analytical batch, but should be randomly distributed through-
out the batch.
The samples should be carefully selected, if possible, from
specimens that have been analysed by the currently used
method, so that the levels of analyte span the analytical range of
the method. Lipaemic, icteric and haemolysed specimens should
be included.
Analyse the samples in duplicate by a comparative method.
The comparative method should be selected with care. Ideally, it
should be a method that has no inaccuracy and small impreci-
sion, which infers that a reference method or definitive method
should be used. Such methods are either unavailable (for
example isotope dilution mass spectrometry) or impracticable.
Therefore the usual practice is to use either the best method that
the laboratory has available or a routine method whose bias and
imprecision are known from, for example, internal and external
quality control arid assurance data.
Figure 3. Familiarization check-list.
Candidate
Action required
prior to evaluation
(1) Method located at site planned for routine use
(2) Services satisfactory: Power
Water
Drainage
Ventilation
Solvent disposal
Radiation disposal
(3) (a) Instruction manual satisfactory
(b) Need to condense/alter instructions for routine use
(4) Problems with reagent preparation/reconstitution
(5) Method components compatible with in-house equipment
(6) Method appears to function according to manufacturer’s expectations
(7) Staff confident of basic operations of method
(8) Approximate time for staff to be confident of usage
(9) Satisfactory results obtained from trial analyses
(10) Safety hazards
(11) Unexpected problems
(12) Sufficient reagents/chart paper/quality-control materials to
proceed with Short or Full evaluation
(13) Manufacturer satisfied with results of familiarization period
128Ideally, the same standards or calibration materials should
be used for both test and comparative methods. Single batches of
reagents should be used throughout for both methods. Where
reagents are unstable, they should be prepared as required from
the same lot of chemicals.
The results of analysis are recorded in columns A and B (for
the test method) and C andD (for comparative method) in figure
4. The other columns may be used for the calculations as
described below. At this point, note the characteristics of both
test and comparative methods in figure 4(b).
Graphical analysis
Plot thefirst result obtained for each sample by the test method
(A) against the first result obtained by the comparative method
(C) on a graph. Both scales should be chosen to accommodate a
range from zero to the highest result generated.
Before proceeding with statistical data analysis, outliers
should be excluded at this stage. Potential outliers are points
which do not lie in the main cluster of points plotted. Sample
duplicate results (B for test method and D for comparative
method) should be inspected to check whether a gross blunder,
for example a sample mix-up, has taken place. To identify
outliers by statistical methods is extremely complex, and
therefore a simple visual inspection of data points is re-
commended. If a point is distant from the main cluster and its
duplicate would lie with the main body of points, then the rogue
point can be rejected. Outliers can also be rejected if there are
logical reasons for data discrepancies (for example ifa manipula-
tive error occurred).
Linearity should also be assessed by visual inspection.
Subsequent statistical analysis is carried out on only those
results that fall within the linear range of the test method.
Data analysis
Calculate the mean, standard deviation and coefficient of
variation for the results obtained by both the test and compara-
tive methods.
If calculation facilities are unavailable:
(1) Add all the results in column A (Ex) and divide the sum by
the number ofanalyses (n) to 9ire the mean result (2)for the
test method Repeat for column C (comparative method).
(2) For each pair, calculate, by subtraction, the difference
between the paired results (results in column A--results in
column Bfor the test method, and results in column C
results in column Dfor the comparative method) and record
in the next column the numerical value ofthe difference (d ),
disregardin9 the sign (+_).
(3) Square these differences and record in the next column
(dZ).
(4) Add the resultant values, divide these totals(d ) by twice
the number ofpairs ofsamples analysed (2n), and take the
square roots of these numbers to obtain the standard
deviation for both test and comparative methods.
(5) Calculate the coefficients for the test and comparative
method from the formula:
SD
CV=--.
It is recommended that, since the imprecision may depend on
the level of analyte, the results be divided into three groups (low,
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medium and high results), ifthere are at least 20 pairs ofresults in
each group. The number of pairs, means, standard deviations
and coefficients or variation for each group are calculated as
detailed above and recorded in the figures 4(a) and 4(b).
F-test
In order to compare the imprecisions of test and comparative
methods, the F-test is used. F is calculated from the ratio of the
square of the larger standard deviation to the square of the
smaller standard deviation. The calculated F should be re-
corded, compared to tabulated values for the appropriate
number of duplicate analyses, and the significance assessed at
various levels of probability (usually 95 and 99) (see
appropriate references in the Bibliography in section X).
’t’-test
The means ofthe sets of results obtained by test and comparative
methods should be qompared using the t-test
If calculation facilities are unavailable:
(1) Derive S
[(nT- 1)ST+ (nc- 1)S]
S
(nr+nc--2)
where nT is the number of analyses performed by the test
method; nc is the number of analyses performed by the
comparative method; S is the square of the standard
deviationfor the test method; and S is the square of the
standard deviation for the comparative method.
(2) Calculate S, the square root of S 2.
(3) Derive from the formula:
(- 2c) / nr nc
S nT+nc
where xT and xc are the means of the results generated
from the test and comparative methods respectively.
Record the value for t. t-Tables should then be consulted, at
the appropriate number of degrees of freedom (n+ nc- 2), to
assess the probability that there is no significant difference
between the two means (usually at 95 or 99 levels) (see
Bibliography in section X).
Linear regression analysis should be performed and the
correlation coefficient, slope, intercept, and, ideally, standard
deviations of slope and intercept should be calculated and
recorded.
If calculation facilities are unavailable:
(a) For the results obtained by the test method, note the
number (nT), and the sum ofall results (XT), and calculate
the mean
nT
(b) Calculate the sum of the squares of the test results Zx2r.
(c) Calculate the square of the sum of the test results (ZXr)2.
(d Calculate
(:xr)
2
which is equal to Y.(Xr-2r)2.
(e) Follow the above proceduresfor the comparative method
to derive
(Xc)
which is equal to E(Xc-:c)2.
129G. H. White and C. G. Fraser The evaluation kit for clinical chemistry
(f) Multiply the two figures derived in Steps (d) and (e) and
take the square root to give
x/Z(x ) (Xc c).
(g) Multiply each value OfXT by the corresponding valuefor xc
and then add all the values together to give EXT’Xc.
(h) Multiply the sum ofall the resultsfor XT(EXT) by the sum of
all the resultsfor xc(EXc) and divide by the number ofpairs
of observations to give
(i) Subtract the number obtainedfrom the number obtained in
Step (g) to give
,XT" XC
.,XT" XC
Figure 4 (a).
Test method
No.
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
4o
41
42
43
44
45
46
47
48
49
5O
A B d
Result Result
(j) Calculate r by dividing the number generated in Step (i) by
the number obtained in Step (f)
Exr’Exc Exr’xc- n
/Z(x-). Z(Xc-)
(k) Calculate the regression equation
xr=a’xc+b
where
and
Summary
Z(x-)(Xc-c)
a--
E(xr-r)
b=r-a.c.
At this stage, a brief summary of the results of this short
evaluation should have been collated and recorded; also record
Inaccuracy and imprecision.
Comparative method
d C D d d
Result Result
continued
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Test method
No. A B d
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
TOTAL
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Inaccuracy and imprecision (continued).
Comparative method
d C D d d
X Mean of A-
n
Standard deviation= /(Zd2)=
/ \ 2nJ
(larger SD) F--
(smaller SO)
Mean SD n
Mean SD n
Mean SD n
Low results
Medium results
High results
Mean of C
n
Standard deviation=
X/k, 2n ,]
significance
Mean SD n
Mean SD n
,Mean SD n
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Figure 4 (b). Short evaluation summary.
Supplier:
Batch or model No.:
Reagent(s):
Standard(s)
Supplier:
Batch or model No.:
Reagent(s):
Standard(s)
Overall
Low results
Medium results
High results
Regression equation:
Test method
Test method
Comparative method
Imprecision
Test method
n Mean SD CV
Comparative method
n Mean SD CV
Inaccuracy
x Comparative method__+
t-- n--
THE FOLLOWING SECTIONS, IN CONJUNCTION WITH THE
FOREGOING EXPERIMENT, CONSTITUTE A FULL
EVALUATION
(2) Between-day imprecision
Materials
At least three specimens are selected for analysis.
Great care must be taken to select materials (either pooled
material from specimens from patients or quality control
materials) with appropriate levels of analyte. It is recommended
that:
(1) Where the analyte has a lower and upper medically
significant decision level (for example plasma sodium)
the low, medium and high materials should have analyte
levels at the low decision level, mid-point of the reference
interval and upper decision level.
(2) Where the analyte does not have a lower medically
significant decision level (for example plasma bilirubin)
the low, medium and high materials should have analyte
levels at the upper limit of the reference at the decision
level and near the extreme upper range capability of the
method.
Liquid materials have a number of advantages, but, before
use, should be subdivided into aliquots and separately frozen.
Lyophilized material must be reconstituted using an identical
protocol throughout the experiment, or, ideally, sufficient
lyophilized material for the experiment should be reconstituted
and pooled and then aliquots prepared and separately frozen.
The characteristics of the materials used should be recorded.
Procedure
Analyse one sample of each of the materials selected on each of
20 days or in 20 separate analytical batches spread over a
number of working days. Ideally, the three or more materials
should be analysed in purely random order amongst a run of
specimens from patients; by this strategy the previously de-
scribed within-run imprecision and inaccuracy experiment and
assessment ofbetween-day imprecision can be performed simul-
taneously. Ideally, a single batch of reagents should be used
throughout this experiment. Where reagents are unstable, they
should be prepared as required from the same lot of chemicals.
Record the results of the analyses in column A on the check-
list; columns B and C may be used, ifrequired, for calculations of
standard deviation as described below.
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Data analysis
The means and imprecisions, as standard deviation and coeffi-
cient of variation, are calculated. 99"870 confidence ranges are
calculated as the mean 3SD. Any results falling outside this
range (outliers) are rejected. Further analyses, equal to the
number of outliers, should be the performed and new means and
imprecisions calculated.
If calculation facilities are unavailable:
(1) Add all the results in column A.
(2) Divide this total by the number ofanalyses (n) to give the
mean value (2).
(3) Use column B to list values of result-mean (x-2).
(4) Use column C to list values of (result-means)
2 (x-2)2.
(5) Add the values in column C to obtain E(x- x)2, divide this
by the number ofanalyses-1 (n-1), and take the square
root of this number to obtain the standard deviation.
(6) Divide the standard deviation by the mean to obtain the
coefficient of variation.
Record the results of statistical analyses.
Figure 4 (c). Between-day imprecision.
Materials
Type:
Supplier:
Batch No.:
Type:
Supplier:
Batch No.:
Type:
Supplier:
Batch No.:
Low
Medium
High
Between-day imprecision: Results for low material
No.
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Total
A B (A-Mean) C (A-Mean)
Result Calculation Calculation
,X
Mean ()=
n
Standard deviation (SD)=
\ n-1 ,/=
SD
Coefficient of variation
Mean__+ 3 SD range is to
continuedFigure 4 (c). Between-day imprecision (continued).
Between-day imprecision: Results for medium material
No.
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Total
A B (A-mean) C (A-mean)
Result Calculation Calculation
.,X
Mean(Y)
Standard deviation (SD)= /(E(x-2)2) \ n-1 ,/=
SD
Coefficient of variation
x
Mean +__ 3 SD range is to
Between-day imprecision: Results jbr hiyh material
No.
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Total
A B (A-mean) C (A-mean)
Result Calculation Calculation
X
Mean(if)
Standard deviation (SD)= \ _
SD
Coefficient of variation-
x
Mean +_ 3 SD range is to
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Graphical analysis
In order to check for changes in inaccuracy during the experi-
ment (drift) and to assess stability of the materials, all results are
plotted as graphs.
The individual results obtained are plotted for each day of
the experiment.
The scale of the ’results’ axis should be chosen to be
equivalent to the total range of results generated.
The graphs should be assessed visually for drift and/or
instability. If this has occurred, then the experiment should be
repeated taking corrective procedures such as selection ofmore
stable materials or preparation of fresh reagents for each run.
(3) Within-run imprecision
Procedure
One sample of each of the materials used in the evaluation of
between-day imprecision is analysed 20 times in a single batch. If
the instrument or reagent kit cannot handle this number of
specimens in one analytical run, perform the maximum number
of analyses possible. An alternative approach, which may be
suitable for single or small vial reagent kits, is to reconstitute
sufficient vials to provide reagent for 20 tests, pool the reagent
and run the analyses.
Record the results of analysis as shown in figure 4 (d).
Data analysis
Calculate the means, standard deviations and coefficients of
variation as described above. Check for outliers, reject as
detailed above, and recalculate the statistical parameters. Re-
cord the results of statistical analysis.
Figure 4 (d). Within-run imprecision.
Results for low material
No.
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Total
A B (A-mean) C (A-mean)
Result Calculation Calculation
X
Mean(if)
Standard deviation (SD)= /(E(x-2)2
4\ n-1 //
SD
Coefficient of variation
Mean_+ 3 SD range is to
continued
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Figure 4 (d). Between-day imprecision (continued).
Within-run imprecision: Results for medium material
No.
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Total
A B (A mean) C (A-mean)
Results Calculation Calculation
,X
Mean(Y)=
Standard deviation (SD)=
’q (2(x [)2) -n_
SD
Coefficient of variation
Mean_+ 3 SD range is to
Within-run imprecision: Results for high material
No.
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Total
A B (A-mean) C (A mean)
Result Calculation Calculation
Mean()
n
Standard deviation (SD)=
/ \ n-/(Y’(x-ff)2)
SD
Coefficient of variation
Mean_+ 3 SD range is to
134
(4) Assessment of inaccuracy using control materials
Commercially available control materials or calibration
materials may have assigned values. These assigned values may
be inaccurate because foreign materials and non-human
materials have been added during manufacture and the physical
and chemical properties may not truly reflect those ofspecimens
from patients. However, if materials from a variety of sources
give results by the test method that differ from those assigned,
then that method is unlikely to have a satisfactory standard of
accuracy. Materials which have been used in inter-laboratory
quality assurance sclaemes (and therefore have had a consensus
value for an analyte derived from many laboratories) are
particularly useful for this part ofthe evaluation. Ideally, a range
ofmaterials should be selected that represent the various types of
base material currently used and contain different levels of
analyte.
Procedure
Analyse at least six different materials in triplicate. These
replicate analyses are performed in different analytical batches.
The results are recorded as shown in figure 4 (e). The mean ofthe
set of three results is calculated and recorded and the mean
compared to the assigned or consensus value. For each mean
result, calculate the allowable error using the formula:
2SD
Allowable error + + 1"2 x SD. /No. of replicates
The between-day SD appropriate to that level of analyte is
used in this formula.
Record the allowable error and an overall assessment of all
results.
(5) Evaluation of linearity
Many methods use a simple one-point or two-point calibration
or standardization technique. The assumptions are then made
that the method is linear at least between the origin and the level
of the one-point calibration or between the two levels of a two-
point calibration. Since good linearity is usually a necessary
prerequisite for acceptable inaccuracy, it must be objectively
assessed and not assumed.
Procedure
Pipette into labelled tubes, in duplicate, samples of a specimen
from a patient; the specimen should be selected to have a.high
level of analyte. Suitable volumes are:
0, 0"2, 0"4, 0"6, 0-8 and 1"0 ml (or multiples thereof).
To one set of tubes add:
1.0, 0"8, 0"6, 0.4, 0.2 and 0ml (or appropriate multiples)
ofdistilled water, physiological saline or appropriate diluent, for
example hormone-depleted serum for immunoassay techniques.
To the other set of tubes, add:
1.0, 0-8, 0-6, 0.4, 0.2 and 0ml (or appropriate multiples)
of a specimen from a patient which has a low level of analyte.
Note the volumes Used as shown in figure 4 (f).
Analyse both sets of samples in duplicate and insert the
results as indicated in figure 4 (f). The duplicate analyses should
be performed in different analytical batches.
Graphical analysis and calculations
On graph paper, plot the mean result obtained for each sample
against the volume of high sample used
Inspect the plots visually and draw the best straight line
through the points.Type:
Supplier:
Batch No.:
Type:
Supplier:
Batch No.:
Type:
Supplier:
Batch No.:
Type:
Supplier:
Batch No.:
Type:
Supplier:
Batch No.:
Type:
Supplier:
Batch No.:
Figure 4 (e).
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II
Analysis of control materials.
Material Results Mean Error Assigned Value
No. Vol. sample
Figure 4 (f). Linearity.
High sample diluted with water/saline/other
Vol. diluent Result Result Mean Error
No. Vol. high sample
High sample diluted with low sample
Vol. low sample Result Result Mean Error
In order to further assess linearity in a more objective
manner, find the between-day imprecision appropriate for each
specimen analysed. Calculate the allowable error for each
specimen analysed using the formula:
2xSD
Allowable error + + 1.4 x SD x/No. of replicates
and record the appropriate allowable errors as shown in figure
4(f).
Assess whether the plotted point for each mean of duplicate
analyses differs from the line ofbest fit by less than the allowable
error: the method is linear where this criterion is fulfilled. Record
the overall assessment of the linearity.
(6) Recovery
An additional aid in the assessment of inaccuracy is to measure
the amount of analyte in a sample following the addition of a
known amount of pure analyte. Such recovery experiments are
particularly useful in the evaluation of analytical methods in
which significant losses may occur, for example, extraction
procedures or chromatographic analysis.
Recovery experiments may be very difficult to design if the
analyte is not available or exists only in a non-physiological
form. In addition, since analyte is added to material already
containing the analyte, analyses may be required to be perfor-
med at the upper extreme of the method’s analytical range. All
recovery experiments require some type of addition of material
which may well change the matrix in subtle and undefined ways.
Similarly, treatment ofspecimens from patients prior to addition
of analyte, for example charcoal stripping to remove hormones,
may markedly alter the nature ofthe matrix. Therefore, recovery
experimems should only be attempted if there is confidence that
the matrix is minimally affected by any addition.
Procedure
A number of specimens from patients can be combined to
provide a base pool. Ideally, the pure analyte is weighed directly
into a small volume ofthe base pool in a volumetric flask and the
volume made up to the mark with the base pool. Alternatively,
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Figure 4 (g). Recovery.
Pure analyte:
Supplier:
Batch No.:
Form added:
A B C
Sample Results Mean
P
1.
Pool 2.
1o
Pool+ 2.
1o
Pool+ 2.
1o
Pool+ 2.
D
Recovery
C-P
E
Expected
F
Percentage
C-P
100o E
the analyte can be dissolved in a small amount of a suitable
solvent. Aliquots of either of these preparations are added to
aliquots of the base pool and the resulting samples and the base
pool are analysed, in at least duplicate, in different analytical
batches. At least three samples should be assessed. The pure
analyte should be added to raise the level of the base sample by
approximately 20, 50 and 100. The amounts added should
not cause the total analyte concentration to exceed the upper
range limit of the method.
The data from the analyses are recorded as indicated in
figure 4 (9).
Data analysis
The amount added to aliquots of the base pool are recorded in
column A, results obtained are recorded in column B and the
mean of the duplicate analyses calculated and recorded in
column C. Subtract the mean result for the base pool from the
means of all other results and insert the data in column D. List
the level of analyte expected to be recovered (the amount added,
adjusted for volume if necessary) in column E and calculate the
percentage recovery as the amount found divided by the amount
added x 100, that is:
value in column D
percentage recovery x 100.
value in column E
Calculate and record the mean recovery.
(7) Specificity and interference
Inaccurate results may occur because constituents present in
samples react and contribute to the final reading: this is
described as lack ofspecificity. For example acetoacetate, which
may occur at high levels in plasma specimens from diabetic
patients, reacts with the alkaline picrate reagent used for
creatinine determination to give falsely high results. Interference
occurs when constituents in samples do not react in the method
themselves but produce low results (inhibition) or high results
(enhancement). For example, enhancement by haemoglobin may
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occur in any colorimetric method where measurements of
absorbance are made in the region at which haemoglobin itself
absorbs.
Careful review of the chemical and/or physical principles of
the test method can identify constituents that may potentially
cause problems. It is a difficult task to test for nonspecificity and
interference since any drug, nutrient or constituent must be
considered as having the potential to cause inaccuracy until it
has been experimentally proved to have no effect.
The vast range of drugs in current use poses particular
problems. Drugs may interfere in the chemistry of the method
(for example prednisolone may give falsely elevated results with
plasma cortisol reagent kit sets), or may cause physiological
changes which affect laboratory tests (for example oral con-
traceptives can cause elevated plasma thyroid hormone or
cortisol concentrations by raising the respective plasma-binding
protein levels). The former type of effect can be simply inves-
tigated; experiments can be performed in a manner similar to
those detailed here,that is addition of drug to specimens from
patients with known levels of.analyte and subsequent re-assay.
The literature on known drug interferences should certainly be
consulted (see Bibliography in section X).
It is recommended, as an absolute minimum, that the effects
of bilirubin, haemoglobin and lipaemia be investigated.
Procedure
Prepare a base pool of specimens from patients which are not
icteric, haemolysed or lipaemic. Select further specimens that
have significant icterus, haemolysis and lipaemia. The true level
ofthe analyte in these latter samples must be assessed. Therefore,
analyse these by the comparative method and record the results as
shown in figure 4 (h). If the comparative method is specific, then
the true values for the analyte are found. If, in contrast, the
comparative method suffers from lack of specificity, alternative
approaches are:
(1) Analysis of the specimens in another laboratory which
has a suitable ’reference’ method, for example analysis of
lipaemic samples for sodium could be carried out
direct ion-selective electrode technology.Figure 4 (h).
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Specificity and interference.
lcterus
No.
Base pool
Vol. pool A Vol. sample B)
Icteric sample=
Bilirubin (C)
Bilirubin
Calc. result (D) Found (mean) (E) Interference (F)
Haemolysis
Base pool
Vol. pool A Voi. sample (B)
Haemolyzed sample=
Haemoglobin (C)
Haemoglobin
Calc. result (D) Found (mean) (E) Interference (F)
Lipaemia
Base pool Lipaemic sample=
No. Voi. pool (A) Vol. sample (B) Triglycerides (C)
Triglycerides
Calc. result (D) Found (mean)(E) Interference (F)
(2) Analysis of samples of base pool with known values of
bilirubin and haemoglobin which have been generated
by addition ofappropriate volumes of specially prepared
solutions of bilirubin and haemoglibin to aliquots of the
base pool.
Analyse the three samples for bilirubin, haemoglobin and
triglycerides respectively, using the best methods available in the
routine laboratory, and record the results as indicated in figure
4 (h). Prepare three series of aliquots of the base pool in labelled
tubes.
Suitable volumes are:
0, 0.2, 0.4, 0.6, 0.8 and 1.0ml (or multiples thereof).
To these samples, add:
1, 0, 0.8, 0"6, 0.4, 0.2 and 0ml (or appropriate multiples)
ofthe icteric, haemolysed and lipaemic samples to generate three
series of samples with linearly increasing levels of icterus,
haemolysis and lipaemia respectively. Analyse these samples, at
least in duplicate, in separate batches and record the mean ofthe
results as shown in figure 4 (h).
Data analysis
From the relative volumes of base pool (column A) and sample
with potentially interfering constituent (column B), calculate the
expected results and record in column D. Subtract these results
from the results found and record the interference in column F.
From the level of potentially interfering constituent (which
should be calculated and recorded in column C), examine
whether the interference is directly proportional to this level. If
the interference is directly proportional, calculate the effect as
units of test method analyte per unit of interfering constituent.
Record the overall interferences found.
(8) Detection limit
The detection limit is the smallest single result which can be
distinguished from a true blank and should be used as the
practical lower limit of the measurement range.
Procedure
Select at least five samples which are suitable blanks. A true
blank is the matrix that is devoid of the analyte assayed by the
test method. If true blanks are unavailable, they can be
simulated by omission ofa crucial reagent or a critical part ofthe
analytical procedure (for example incubation). Analyse these
samples in duplicate and record the results as shown in figure
4(0. Since the imprecision of the method may have been
significantly changed by this analytical modification the impre-
cision of the method at very low levels of analyte should be
measured. Carefully select at least five samples which have very
low levels ofanalyte and which therefore will have readings close
to the range given by the true or simulated blanks. Analyse these
samples in duplicate and record the results as indicated in figure
4(i).
Data analysis
Calculate the mean and standard deviation of the true or
simulated blanks from the formulae:
Similarly calculate the standard deviation of the samples
with the low levels of analyte. The two standard deviations
should be similar; this hypothesis can be tested using the F-test.
If the standard deviations for the blanks and the low level
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Figure 4 (i). Detection limit.
True blanks
No. Result Result 2 Calculation (d) Calculation (d 2)
Totals
No. Result
No. of pairs (n)=
Ex
mean (2)=
n
SD=Nt \-n/
Low samples
Result 2 Calculation (d) Calculation (d 2)
Totals
No. of pairs (n)=
Zx
mean (2)-
n
SD=,q \---n]
Figure 5. Full evaluation summary.
Re-evaluate data from short evaluation: figure 4 (b).
Imprecision
Between-day
n Mean SD CV n
Within-run
Mean SD
Low
Medium
High
Quality control materials
Are the assigned values obtained?:
Are there problems or potential problems with materials?:
Mean recovery:
Recovery
Linearity
Upper limit of linearity
(sample diluted with water/saline/diluent):
Upper limit of linearity
(high sample diluted with low sample):
Specificity and interference
Interference with icterus: per
Interference with haemolysis: per
Interference with lipaemia: per
Detection limit
Detection limit:
bilirubin
haemoglobin
triglycerides
CV
138analyses are similar the detection limit may then be calculated
from the approximate formula:
Detection limit mean of true blank 2.8 SD.
Record the detection limit.
If the standard deviations are significantly different, other
methods of simulating true blanks will have to be found.
Section VII: Specific studies
Section VI detailed an evaluation protocol that is applicable
to all methods, instruments and reagent kit sets. However, most
methods possess features that are unique to themselves and
clearly these singular aspects should also be subject to rigorous
evaluation. Therefore specific studies form the second major
experimental component of a complete evaluation.
The aim of these specific studies is to detect, in the test
method, any problems that exist or may arise with:
(1) Component performance.
(2) Method chemistry.
It is important to realize that these specific studies must be
carried out regardless ofwhether the test method performed well
or poorly in the Section VI evaluation. Enduring good perfor-
mance will be dependent upon the individual components
continuing to function to the same standards reached during the
evaluation. An unacceptable outcome in Section VI may be
traceable either to components that comprise the test method
itself, or to components that have to be supplied by the
laboratory. In either case the components, for example pipettors,
radioactivity counters and colorimeters, must be individually
evaluated to ensure that they function optimally and will
continue to do so after the complete evaluation is concluded.
A general evaluation cannot account for all the types of
specimen that the test method may be called on toanalyse.
Therefore, specific studies should be designed to explore the
effects of potential samples on the chemistry of the test method.
Such studies should pay particular attention to differences
between human and animal sera, since many quality control and
assurance sera use the latter matrix.
Clearly, it is not possible to detail protocols that will embrace
the special studies required for the range of currently available
instruments and reagent kit sets. Therefore those areas that are
strongly recommended as candidates for specific studies are
briefly listed below. The Bibliography (section X) should be
consulted if guidance about individual experimental design is
required.
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Incubators:
Temperature stability
Warm-up time.
Diluters/dispensers/samplers:
Imprecision and inaccuracy
Specimen-cross contamination
Specimen-diluent contamination.
Enzyme analysers:
Achievement of true end-point
Optimal conditions
Cofactor concentration
Analyte level at which substrate depletion occurs.
Reagents and reagent kit sets:
Labelling requirements
Stability and shelf-life.
Samples:
Diluted patient specime.ns
Bovine and other animal quality control materials.
Ligand assay reagent kit sets:
Standards in aqueous solution, bovine, or human sera
Effect of total protein concentration on separation
procedures
Effect of small variations in timing ofprocedures, such as
incubation and separation
Effect of small variations in temperature on procedures
Dilution of sample to parallel standard curve
Cross-reactivity
Time to obtain an adequate number of counts.
Scintillation counters:
Calibration
Efficiency
Effect of sample size and position
Background
Line-voltage stability
Channel width
Dector equivalence in multi-well counter
Linearity
Efficiency of scintillation cocktails.
Data reduction:
Errors of manual and automated calculation of results.
Balances:
Inaccuracy and imprecision.
Manual tests:
Adaptability to mechanization or automation.
Spectrophotometers:
Wavelength range
Band width
False light
Temperature control
Linearity
Inaccuracy and imprecision
Warm-up time.
Mechanized analysers:
Carry-over
Specimen-cross contamination
Specimen-diluent contamination
Drift
Reagent usage
Automatic calculation of results from raw data.
Section VIII: Acceptability criteria
It is a difficult task to decide whether the test method is
acceptable: there is little published work to aid in this decision. A
logical sequential flow-diagram is presented in figure 6 to help
decision-making.
Criteria for acceptance or rejection of the method are as
follows.
(1) Within-run imprecision
After outliers have been rejected on objective grounds, the
within-run imprecision of the method can be accepted as
satisfactory if the SD is equal to or less than half of the intra-
individual biological variation of the analyte (the ideal), or
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Within-run imprecision Plot data
Reject outliers
Calculate SD
Acceptable?
Yes No
Can imprecision
be improved?
Yes No
Comparison of methods
Reject
Calculate linear regression and
equation
Acceptable?
Yes No
Can inaccuracy
be improved?
Yes No
Between-day imprecision and_._
within-run mprecision
Consider
Calculate SD
rejection
Acceptable’
Yes No--Reject outliers
and plot graphs
Acceptable’
Yes No
Can imprecision
be mproved’
Ces. No
Quality control materials
Reject
Assess inaccuracy
Accetable’
Yes No--i.-Examine materials
AccePtable?
No Yes
Can accuracy
be improved?
Yes No
Recovery Consider
rejection
Assess data
Acceptable?
Yes No--Examine data carefully
No Yes
Can recovery
be improved?
Yes No
Linearity
Specificity and interference-----
Detection limit Consider
rejection
Define acceptable
samples for analysis
Specific studies I
Assess data
Acceptable?
Yes No----- Consider improvement
rejection
Accept method
Figure 6.
criteria.
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Logical sequentialflow diagramfor acceptability
fulfills another satisfactory analytical goal for imprecision (see
Bibliography in Section X). If the SD is greater than the goal,
assess whether the method can be improved by, for example,
introduction of replicate analyses or modification of the type
and level of standard. If the method cannot be improved, reject
it.
(2) Comparison of methods
Interpretation of the statistics used for comparison of methods
data is particularly difficult, especially if the comparative
method is far from ideal itself (see Bibliography in Section X).
The test method can be accepted:
(a) If r is greater than 0-99.
(b) If the slope is not significantly different from 1.00.
(c) If the intercept is not significantly different from 0.
(d) If shows that the means are not different.
If these criteria are not fulfilled, assess whether the method can
be improved by, for example, use of different standards. If the
method cannot be improved, seriously consider rejection unless
acceptance can be fully justified on objective clinical grounds.
(3) Between-run and within-run imprecision
The criteria adopted for within-run imprecision should also be
applied here.
(4) Quality control materials
If the results obtained by the test method are not significantly
different from the assigned values, that is the assigned value lies
within the result + allowable error, accept the method. If the
results are different, examine whether the quality control
materials themselves pose problems that do not occur with
specimens from patients, for example turbidity caused by
lyophilization. If the materials are suspect, accept the method. If
the materials are not suspect, assess whether the accuracy of the
method can be improved. If the method cannot be improved,
seriously consider rejection unless acceptance can be fully
justified on objective clinical grounds.
(5) Recovery
If the mean recovery is 90-110, and no individual recovery is
less than 85 or more than 115, accept the method. If these
criteria are not fulfilled, re-examine the design of the recovery
studies. If the experiment could only be performed in a non-
ideal manner, for example if iron was added as a solution of iron
metal in hydrochloric acid and significant pH changes sub-
sequently occurred, the results can be regarded with scepticism
as to their validity.
(6) Specific studies
Assess data derived from all specific studies. If the results are
satisfactory, accept the method. Ifthe results are not satisfactory,
give careful consideration as to whether an improvement is
technically possible at reasonable cost. Otherwise, consider
rejection of the method.
(7) Method acceptance and definition of samples
The test method is acceptable if all the above criteria are fulfilled.
Careful assessment of linearity, specificity and interference, and
detection limit should be undertaken to define those samples
that are not suitable for analysis by the method.Section IX: Introduction to service
If the evaluation, specific studies and the final assessment of
performance has led to an objective decision to accept the test
method, then the method is ready to be introduced into routine
service. Before the method finally becomes operational in the
routine setting there are a number of important ancillary tasks
to be completed.
(1) Preparation of work site if evaluation has been perfor-
med in a special area.
(2) Training of staff in the operation and performance of the
test method, maintenance, and trouble-shooting; educ-
ation of staff on the principles of the method and its
chemistry; guidelines for emergency and out-of-hours
use and associated trouble-shooting.
(3) Preparation of work-lists, quality control and decision
criteria for monitoring of performance, interfaces if on-
line data reduction is envisaged and reporting systems.
(4) Purchase of sufficient reagents, quality control materials,
and spares and consumables and organization of
storage. Assessment of reliability of manufacturer or
agent to provide standing orders or regular delivery.
(5) Determination of reference interval if the evaluation
studies revealed that the new method requires a reference
interval that is significantly different from current usage.
(6) Preparation of a routine maintenance schedule and
associated check-list.
(7) Preparation of an insert for the laboratory method
record, detailing clinical use of method, method prin-
ciple, source of method, specimen collection require-
ments, standards, quality control, reagent composition,
procedure, result units, and relevant cautions (effects of
lipaemia, haemolysis, drugs etc.).
(8) Enrolment of the method in an external quality
assurance scheme.
(9) Communication with all laboratory users ifthe introduc-
tion of the new method will alter specimen requirements,
reference intervals or turnaround time of results.
Although the new method has now been fully evaluated and
installed into the routine laboratory the completed ’Evaluation
Kit’ should not be discarded. The data contained in it comprise
as full an objective description of the new method that it is
usually possible to have, specifying how the method actually did
perform in all relevant aspects. Therefore the ’Evaluation Kit’
provides the bench-mark against which all future quality control
and assurance programme results can be compared.
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